Hand-held spectral-domain optical coherence tomography of small macular retinoblastoma in infants before and after chemotherapy.
OBJECTIVE
To demonstrate the utility of hand-held spectral-domain optical coherence tomography (SD-OCT) in assessing retinal structure in cases of macular retinoblastoma.


METHODS
In this retrospective, observational case series, three young children with macular retinoblastoma were treated at a tertiary care hospital. At examination under anesthesia, each patient was evaluated with SD-OCT for analysis of retinal tumor and macula. The main outcomes were retinal morphology before and after chemotherapy.


RESULTS
The mean patient age was 16 months (median: 9 months; range: 7 to 33 months). All patients had small exophytic macular retinoblastoma with subretinal fluid in the foveola. At presentation, the mean tumor thickness was 4.8 mm (range: 4.0 to 6.0 mm) and mean tumor base was 10.3 mm (range: 8.0 to 12.0 mm). SD-OCT documented tumor surface as smooth (n = 2) or irregular (n = 1), involvement of full-thickness retina (n = 3), and optical density as low (n = 3). The surrounding retina showed abrupt transition to tumor (n = 3), without intraretinal edema (n = 3), and with underlying subretinal fluid (n = 3). Following chemotherapy, all tumors showed regression with mean thickness of 2.6 mm (range: 2.2 to 3.0 mm). SD-OCT documented tumor surface as smooth (n = 1) or irregular (n = 2), and optical density as medium (n = 1) or high (n = 2). At the tumor site, the retina showed full-thickness disorganization but with abrupt transition to normal retina (n = 3). The foveola was anatomically intact (n = 1) or with outer retinal thinning (n = 2). Subretinal fluid was resolved in each case (n = 3).


CONCLUSIONS
SD-OCT can provide precise anatomic monitoring of the macular region in infants and young children with small macular retinoblastoma. This may serve as a guide for visual potential in the preverbal child.
Christopher
C
Cao
Michele
M
Markovitz
Sandor
S
Ferenczy
Carol L
CL
Shields
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008266:Macula Lutea / Q000187:drug effects / Q000473:pathology; D008297:Male; D012160:Retina / Q000187:drug effects / Q000473:pathology; D019572:Retinal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D012175:Retinoblastoma / Q000188:drug therapy / Q000473:pathology*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence
D000970:Antineoplastic Agents